In Brief: Sensor Pad
This article was originally published in The Tan Sheet
Sensor Pad: Sales restriction merits reconsideration by FDA, the House Appropriations Committee states in its FY 1997 budget. During budget mark-up this month, the committee unanimously accepted Rep. Barbara Vucanovich (R-Nev.)'s amendment directing FDA "to re-examine the need for `prescription-only' status" for the Inventive Products breast self-examination device and report its findings to Congress within 60 days of enactment. The amendment argues that the restriction "limits availability of this essential tool to low-income women who cannot afford to see a physician in non-emergency situations." Vucanovich introduced a bill (HR 3504) on May 22 that would require FDA to permit OTC distribution of the product...
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC